Highlights Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Market Closed - OTC Markets Other stock markets 03:52:36 2024-05-03 pm EDT			5-day change	1st Jan Change
0.4102 ^USD	+7.58%		+0.05%	-97.76%

May. 01	Certain Stock Options of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI
May. 01	Certain Warrants of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025	Apr. 22	CI
Panbela Announces Poster Presentation At American Association for Cancer Research	Apr. 18	CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell on Expectations for Unchanged Fed Policy Rate	Jan. 29	MT
Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum	Jan. 25	CI
Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma	Jan. 18	CI
Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial	Nov. 29	CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes	Nov. 02	CI
Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication	23-10-25	CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer	23-07-24	CI
Panbela Therapeutics Divests Neuroblastoma Assets in Deal Valued at Up to $9.5 Million	23-07-19	MT
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial	23-07-10	CI
Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis	23-06-28	CI
Panbela Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Panbela Therapeutics Inc. Announces Poster Presentation at American Association for Cancer Research: Evaluating Potential of Spermine Analogue Ivospemin (SBP-101) in Combination with Chemotherapy in Ovarian Cancer	23-04-19	CI
Panbela Regains Worldwide Rights to Develop and Commercialize Flynpovitm in Patients with Familial Adenomatous Polyposis	23-04-11	CI
Panbela Therapeutics, Inc. Announces Acceptance of CPP-1X Abstract for Poster Presentation At Immunology of Diabetes Society Meeting	23-04-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Highlights

Filters